We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Calithera Biosciences (CALA) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Calithera Biosciences (CALA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Calithera Biosciences is one of 890 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CALA is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for CALA's full-year earnings has moved 13.95% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, CALA has moved about 16.99% on a year-to-date basis. In comparison, Medical companies have returned an average of -3.65%. As we can see, Calithera Biosciences is performing better than its sector in the calendar year.
Looking more specifically, CALA belongs to the Medical - Drugs industry, a group that includes 171 individual stocks and currently sits at #19 in the Zacks Industry Rank. On average, stocks in this group have lost 9.79% this year, meaning that CALA is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on CALA as it attempts to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Calithera Biosciences (CALA) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Calithera Biosciences (CALA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Calithera Biosciences is one of 890 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CALA is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for CALA's full-year earnings has moved 13.95% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, CALA has moved about 16.99% on a year-to-date basis. In comparison, Medical companies have returned an average of -3.65%. As we can see, Calithera Biosciences is performing better than its sector in the calendar year.
Looking more specifically, CALA belongs to the Medical - Drugs industry, a group that includes 171 individual stocks and currently sits at #19 in the Zacks Industry Rank. On average, stocks in this group have lost 9.79% this year, meaning that CALA is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on CALA as it attempts to continue its solid performance.